Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Lonza : New eCHO Basal Medium and Feed Facilitates Late-Stage Cell Viability and a Consistent Yield of High Integrity Proteins

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/14/2019 | 08:11am EST

Basel - Lonza has further expanded its cell culture media portfolio with the addition of the eCHO Basal Medium and Feed, which has been designed to optimize protein production by delivering a consistent yield and highly viable cells while keeping lactate levels to a minimum for optimal protein integrity.

Researchers working in the manufacture of recombinant proteins for medical use can now benefit from this new serum-free, chemically defined, hydrolysate-free and non-animal origin medium to advance cell proliferation and enhance productivity.

The benefits enabled by using Lonza's paired eCHO Basal Medium and Feed will be presented during the 2019 PEGS Europe (18-22 November, Lisbon, Portugal) and Antibody Engineering and Therapeutics (9-13 December, San Diego, California) conferences.

Chinese hamster ovary (CHO) cells are commonly used in the manufacture of biotherapeutics, such as monoclonal antibodies, complex glycoproteins and biosimilars. To facilitate the growth of healthy and viable CHO cell cultures for subsequent protein production, it is of utmost importance to use a high-quality medium. However, the lactate typically generated in the course of protein production can have a profound impact on protein integrity, leading to irreproducible, unreliable and misleading results, and even product failure. Furthermore, the clogging of the filters of protein purification systems and the associated product loss are among the most common challenges facing laboratories, and they can severely limit yield.

Lonza's eCHO Medium has been specifically developed to address these challenges. Combining basal and feed medium each as a one powder product, the eCHO Medium enhances late-stage cell viability, accelerating protein purification and allowing for the production of a consistently increased amount of proteins per cell. By minimizing the generation of lactate, the medium also safeguards the integrity of proteins, considerably improving post-translational modifications.

The eCHO Medium is available in both liquid and powder formats to suit varying application throughput needs. Contrary to other similar media available on the market, the powder consists of a single component, minimizing preparation time for rapid and simplified production scale-up. Additionally, the cost-effective components used to produce the eCHO Medium mean that researchers can further benefit from a product that is reasonably priced.

Poster: eCHO Basal Medium and Feed for the CHO cells: Easy, Economical, Chemically Defined Animal Origin-Free, Simple One Part Formulation Medium for the Production of Monoclonal Antibodies

During the 2019 PEGS and Antibody Engineering and Therapeutics conferences, Lonza experts will present the results of a study whereby the eCHO Medium was used to produce monoclonal antibodies. The study demonstrated the ability of the new medium to deliver consistent product quality and performance, while being easy and economical to use. More specifically, Lonza will reveal how the eCHO Medium: Produced approximately 18 million cells per ml with a remarkable 95% viability

Generated a low amount of lactate between 1.5 and 2 g/L, improving product integrity

Produced consistently high titers of 3 g/L

Facilitated the benchmarking and scalability of monoclonal antibody production using bioreactors instead of shake flasks

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.

Contact:

Dr. Kristin Koehler

Tel: +41 61 316 8782

Email: kristin.koehler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
11/27Pfizer, Novartis lead $2 billion spending spree on gene therapy production
RE
11/21LONZA : Navrogen Inc. and Lonza Sign Agreement to Use Lonza's GS Gene Expression..
AQ
11/14LONZA : New eCHO Basal Medium and Feed Facilitates Late-Stage Cell Viability and..
AQ
11/12Board Announcement
TE
11/06CRYOPORT : Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Deliv..
AQ
10/29LONZA : to Host New Webinar 'Paper to EBR in 9 Months How a Strong Collaboration..
AQ
10/23LONZA : Announces Short, Routine Shutdown of Niacinamide Plant in Nansha for Mai..
AQ
10/18MESOBLAST : and Lonza Enter GVHD Commercial Manufacturing Agreement
AQ
10/17LONZA : Strengthens Sports Nutrition Portfolio with the Launch of Vegan MuscleGu..
AQ
10/17MESOBLAST : and Lonza Enter into Agreement for Commercial Manufacture of Mesobla..
AQ
More news
Financials (CHF)
Sales 2019 5 905 M
EBIT 2019 1 204 M
Net income 2019 723 M
Debt 2019 3 215 M
Yield 2019 0,84%
P/E ratio 2019 34,8x
P/E ratio 2020 29,3x
EV / Sales2019 4,83x
EV / Sales2020 4,47x
Capitalization 25 281 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 374,86  CHF
Last Close Price 340,50  CHF
Spread / Highest target 35,7%
Spread / Average Target 10,1%
Spread / Lowest Target -19,2%
EPS Revisions
Managers
NameTitle
Marc Funk Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP33.69%25 505
IQVIA HOLDINGS INC.27.82%28 813
INCYTE CORPORATION48.58%20 351
SEATTLE GENETICS, INC.107.38%20 138
CELLTRION, INC.--.--%18 265
ALNYLAM PHARMACEUTICALS, INC.69.74%13 798